Can Atopic Dermatitis and Seborrheic Dermatitis Occur Simultaneously?
Yes, atopic dermatitis (AD) and seborrheic dermatitis (SD) can and do occur simultaneously in the same patient, though distinguishing between them—especially in infancy—can be clinically challenging.
Evidence for Co-occurrence
The evidence clearly supports that these conditions can coexist:
A 2025 large-scale retrospective cohort study of over 20 million patients found that seborrheic dermatitis was strongly associated with atopic dermatitis (OR 3.21; 95% CI, 3.18-3.24) 1. This represents one of the strongest associations between SD and other epithelial barrier diseases, suggesting shared pathophysiologic mechanisms.
Multiple clinical guidelines acknowledge this overlap. The 2014 AAD guidelines specifically note that "it is often difficult to separate AD from seborrheic dermatitis in infancy, and the two conditions may overlap in this age group" 2. The 2014 acute otitis externa guideline similarly recognizes that "eczema (atopic dermatitis), seborrhea (seborrheic dermatitis), and other inflammatory dermatoses involving the ear canal and surrounding tissue are relatively common" 3, indicating these conditions can affect the same anatomical sites.
A 2025 review on AD with comorbid skin diseases explicitly addresses the diagnostic challenges when AD presents alongside other conditions including seborrheic dermatitis 4.
Clinical Implications and Distinguishing Features
When evaluating a patient with suspected overlap:
Key distinguishing characteristics:
Distribution patterns: AD typically spares the groin and axillary regions, while SD commonly affects these areas along with the scalp, central face, and other sebaceous-rich zones 2, 3
Pruritus: AD is characterized by intense pruritus as a hallmark feature 5, whereas SD tends to be less pruritic or non-pruritic 3
Lesion appearance: SD presents with greasy yellowish scaling and is associated with Malassezia yeast 3, while AD shows eczematous lesions with erythema, xerosis, and age-specific distribution patterns 5, 2
Age of onset: AD typically develops within the first 5 years of life (80% within first year) 5, while the relationship between infantile SD and later AD development remains an area of investigation
The Infantile Overlap Dilemma
The distinction is particularly problematic in infants, where clinical overlap is most pronounced:
A 2014 Greek study found that 34.4% of children diagnosed with infantile SD later developed AD, significantly higher than the 10.7% AD prevalence in the general pediatric population 6
Research suggests that what appears as infantile SD may represent early manifestations of AD in some cases, or that "ISD is a syndrome and not a disease" 7
The diagnostic difficulty stems from atypical AD presentation in infancy, where lesions often occur on the face with erythematous-exfoliative character, overlapping with typical SD locations 8
Management Approach When Both Conditions Coexist
When both conditions are present, treatment must address both pathologies:
For the AD component: Implement barrier restoration with frequent fragrance-free emollients, topical corticosteroids for flares (low-to-medium potency for face/neck), and topical calcineurin inhibitors as steroid-sparing agents 5
For the SD component: Use topical antifungal medications to reduce Malassezia colonization and topical anti-inflammatory agents 3
Avoid common pitfalls: High-potency corticosteroids on the face/neck can cause skin atrophy 5; be aware that some patients may develop allergic contact dermatitis to topical treatments including neomycin (5-15% of chronic cases) 3
Clinical Caveat
The 2014 AAD guidelines emphasize that when a patient is not responding to therapy, the diagnosis should be re-reviewed and other disorders considered 2. This is particularly relevant when managing presumed AD or SD, as the presence of both conditions simultaneously may explain treatment resistance if only one condition is being addressed.
The shared epithelial barrier dysfunction underlying both conditions 1 suggests that comprehensive barrier repair strategies benefit both diseases, making emollient therapy a universal foundation regardless of diagnostic uncertainty.